| Literature DB >> 32499881 |
Shabahang Jafarnejad1, Hamidreza Khoshnezhad Ebrahimi1.
Abstract
Asthma has been known as a prevalent chronic-type inflammatory disease in children, because of their narrower respiratory airways. The present study aimed to identify guidelines for children asthma treatments. Extensive research was conducted on biomedical and pharmacological bibliographic database PubMed, EMBASE, MEDLINE, LILACS database, global independent network of Cochrane, Science Direct and global health library of Global Index Medicus. A comprehensive literature review was carried out using the terms Pediatric Asthma, epidemiology, management, and related clinical guidelines published from 2000 to 2019. After the primary assessment, quick diagnosis, clinical practice guidelines are useful tools for proper management of pediatric Asthma. By setting proper guidelines for this particular population, a higher improvement in quality of management of of pediatric Asthma is expected. Given the differences between the recommendations arisen by BTS/SIGN and NICE guidelines, critical comparison of the evidence-base guidelines provide suggestions that have more in common than what might seems at the first glance. The analysis of the variations presented in the present article will assist clinicians to make accurate decisions regarding their patients.Entities:
Keywords: Emergency Department; Pediatric asthma; child health; clinical guidelines; emergency care
Year: 2020 PMID: 32499881 PMCID: PMC7254431 DOI: 10.4081/ejtm.2019.8682
Source DB: PubMed Journal: Eur J Transl Myol ISSN: 2037-7452
Asthma risk factors
| 1. Preschool children with viral-induced wheeze |
| 2. Children presenting for the first time with a new onset of asthma signs and symptoms. |
| 3. Children with an established diagnosis of asthma that is in exacerbation. |
| 4. Children presenting with asthma-related issues such as not having a replacement inhaler or inappropriate inhaler techniques causing poor response to inhalers administered at home. |
| 5. Children presenting with status asthmatics, characterized by severity and lack of response to repeated doses of inhaled bronchodilators, (severe or life threatening) who may need resuscitation. |
The intensity of exacerbation for children older than five years, derived from the Sheldon et al.[6]
| » Oxygen saturations ≥92% | » Oxygen saturations <92% | » Oxygen saturations <92% |
|---|---|---|
| » Peak expiratory flow rate (PEFR) >50% best or predicted | » PEFR 33-50% best or predicted | » PEFR <33% best or predicted |
| » No features of acute/life- threatening asthma | » Unable to complete sentences | » Silent chest |
| » Heart rate: | ||
| » Respiratory rate: |
Medicines for pediatric asthma exacerbations
| Inhaled, aerosol | » Two to ten puffs: each puff is inhaled separately, repeat every 10-20 minutes or as required, use a large volume spacer | Mild to moderate asthma | » βagonist 2 | |
| Nebulised, driven by oxygen | One month to four years: » 2.5mg every 20-30 minutes or when required | Moderate, severe or life-threatening oxygen saturations <92% | ||
| Intravenous injection (IV) (second line) | Single bolus dose: » 1-23 months: 5mcg/kg over five mins » 2-17 years: 15mcg/kg over five minutes | Severe asthma unresponsive to initial nebulised therapy | ||
| Oral | One month to 12 years old: » 1 to 2mg/kg once daily | Moderate, severe or life-threatening | » Corticosteroid | |
| Nebulised | One month to one years: » 250mcg every 20-30 minutes for first two hours, then 250mcg every 4-6 hours as required 12 to 17 years: » 500mcg every 4-6 hours as required | Severe or life- threatening | » Anticholinergic » Onset of action 20-30 minutes | |
| IV (second line) (patient must not be on oral maintenance theophylline) | 12-17 years: » 500-700mcg/kg/hr, adjusted to plasma-theophylline concentration | Severe or life- threatening resistant to maximum bronchodilator and steroid therapy | Decreases airway inflammation | |
| IV (second line) | 2-17 years old: » 40mg/kg (maximum per dose | Severe or life- threatening and responding poorly to first-line treatments | Relaxes smooth muscle |